Germline mutations in both BRCA2 and CHEK2 are associated with an increased risk for male breast cancer. To search for potential interactions between the products of these breast cancer susceptibility genes, we undertook systematic mapping of BRCA2 for potential phosphorylation sites by CHEK2. In vitro kinase assays and mass spectrometric analysis identified a 50 amino-acid fragment within the N-terminus of BRCA2 potentially targeted by CHEK2, containing two major phosphopeptides. Inducible overexpression of this peptide, but not a derivative with mutated phosphorylation sites, leads to increased chromosome fragmentation and suppression of cellular proliferation. These results suggest a link between CHEK2 and BRCA2 pathways, which may contribute to the spectrum of cancers associated with germline CHEK2 mutations.
CHEK2 (also known as CHK2) encodes an ATM-dependent serinethreonine kinase that modulates a conserved DNA damage checkpoint pathway (Ahn et al, 2004) . Although its orthologs Rad53 (Saccharomyces cerevisiae) and Cds1 (Schizosaccharomyces pombe) are integral components of the G2/M DNA damage checkpoint (Sanchez et al, 1996; Rhind et al, 2000) , mammalian CHEK2 has been reported to mediate phosphorylation of a number of targets, implicated in multiple aspects of cell cycle progression and DNA damage repair (Zhou and Elledge, 2000; Bartek et al, 2001) . By analogy with its yeast orthologs, CHEK2 was first shown to phosphorylate Cdc25C on Ser216, leading to its cytoplasmic sequestration by 14-3-3 proteins, and preventing the dephosphorylation and activation of Cyclin B/Cdc2, thus mediating a G2 arrest (Peng et al, 1997; Sanchez et al, 1997; Matsuoka et al, 1998) . Subsequently, CHEK2 was shown to have additional targets, including Cdc25A (Ser123) leading to its destabilisation and activating the S-phase checkpoint (Mailand et al, 2000; Falck et al, 2001) ; p53 (Ser20), linked to its activation following ionising radiation (IR) and modulating a G1/S arrest (Chehab et al, 2000; Hirao et al, 2000; Shieh et al, 2000) ; and BRCA1 (Ser988), implicated in its altered subnuclear localisation (Lee et al, 2000) . Although these pathways have been studied primarily in cancer cell lines, a number of mouse models of CHEK2 inactivation have provided some insight into the physiologically relevant pathways (Hirao et al, 2002; Takai et al, 2002) . These have demonstrated a mild attenuation of p53 function, with modest tumorigenesis, but significant synergistic effects following inactivation of both CHEK2 and Brca1 (McPherson et al, 2004) .
In humans, CHEK2 inactivation is thought to mediate a moderately increased risk for breast and possibly prostate cancers (Allinen et al, 2001; Meijers-Heijboer et al, 2002; Seppala et al, 2003; Cybulski et al, 2004) . Germline mutations were initially identified in families with Li Fraumeni-like multicancer syndromes lacking the characteristic mutation in p53 (Bell et al, 1999) . Subsequent population-based studies have shown that a recurrent loss of function CHEK2 mutant, CHEK21100delC is present in approximately 1% of the population and in 5% of familial breast cancer families lacking a BRCA1 or BRCA2 mutation (Meijers-Heijboer et al, 2002; Fernandez-Novoa et al, 2004) . The fact that BRCA1/2 kindreds displayed no increase in CHEK21100delC mutation frequency was taken as evidence that CHEK2 may function in a similar pathway, thus obviating the need for redundant mutations. Most significantly, the frequency of CHEK21100delC in breast cancer families with a case of male breast cancer was as high as 13% (Meijers-Heijboer et al, 2002) . Given the relatively unique nature of the link between BRCA2 mutations and male breast cancer, we therefore sought evidence of a functional interaction between BRCA2 and CHEK2.
MATERIALS AND METHODS

Generation of constructs and conditionally expressing cell lines
Overlapping serial fragments of BRCA2, with the exception of the extreme C terminus, which could not be expressed in vitro, were constructed by PCR and introduced into pGEX2T to express GST-fusion proteins. Proteins were expressed in BL21 cells, followed by Glutathione Sepharose 4B bead purification, and dialysis (20 mM HEPES, pH 7.4, 20% glycerol, and 0.5 mM PMSF) of purified proteins. The B2P fragment, containing either wild-type sequence of 50 amino-acids spanning the CHEK2 targets, or a mutated version was fused to a Flag at the N-terminus and SV40 NLS at the C-terminus and cloned into the tetracycline-regulated vector pUHD10.3. Inducible expression of a wild-type B2P (WT), a mutant version with all four serine/ threonine to alanine/valine, or a previously described BRC repeat fragment, BRC4 (Chen et al, 1999) was achieved by co-transfecting a U2OS founder cell line with the corresponding pUHD10.3 construct, along with a plasmid encoding hygromycin resistance. Hygromycin-resistant clones were selected for comparable levels of inducible B2P expression by western blot analysis, and at least two independent clones were selected for each construct for functional assays.
In vitro kinase assays
In vitro kinase assays were performed using either cellular CHEK2 derived from U2OS cells with inducible expression, immunoprecipitated using anti-Flag antibody, 1 h after g-irradiation (10 Gy), or purified bacterially expressed GST-CHEK2 proteins. Various fragments of GST-BRCA2 (B2P-WT or -mutants) were used as substrates in a 30-min incubation using 20 mM HEPES (pH 7.4), 10 mM MgCl 2 , 10mM MnCl 2 , 40mM ATP, and 15 mCi [g-32 P]ATP at 301C.
Cell growth assays and chromosome spreading and GTG banding
Equal numbers of cells (5 Â 10 4 ) with inducible expression of B2P-WT, B2P-M9, or BRC4 were plated onto six-well plates in the presence of tetracycline (1 mg ml À1 ). Tetracycline was withdrawn after 24 h and viable cells were counted at the indicated times. For chromosome analysis, equal numbers of cells (5 Â 10 5 ) were plated, followed by inducible expression of the appropriate constructs and treatment of cells with colchicine (10 mg ml À1 ) for 20 h. Cells were then treated with trypsin and Giemsa for GTG banding as described (Thalhammer et al, 2001) . Individual metaphases were photographed and scored blindly for abnormal structures and broken chromosomes.
Statistical methods
The comparison of mean fragment/metaphase between two groups was performed by two-sided Student's t-test. We performed two comparisons (i.e., comparisons of WT vs BRC4, and M9 vs BRC4), and the Bonferroni's correction was applied to the significance level of each comparison. A P-value o0.025 was considered as a statistically significant result.
RESULTS AND DISCUSSION
To search for potential CHEK2 phosphorylation sites within BRCA2, we first generated a series of overlapping glutathione S-transferase (GST)-fusion proteins spanning the BRCA2 coding sequence, with the exception of the extreme C terminus, which could not be expressed in vitro (Figure 1 ). Purified GST-BRCA2 fragments were incubated with either bacterially expressed GST-CHEK2 or with immunoprecipitates of CHEK2 derived from X-irradiated (10 Gy) U2OS cells expressing a tetracycline-regulated Flag-tagged construct. A single N-terminal fragment of BRCA2 (amino acids 1 -450) showed reproducible in vitro phosphorylation by both GST-CHEK2 and immunoprecipitated CHEK2 proteins, comparable in intensity to the 988 Serinecontaining BRCA1 fragment previously identified as a CHEK2 Figure 1 Phosphorylation of the N-terminal fragment of BRCA2 (B2P) by CHEK2 in vitro. Schematic representation of BRCA2 in seven overlapping GSTfusion proteins, designated 1 -7, and used for in vitro kinase assays. Fragment 1 was further subdivided into the three overlapping GST-fusion proteins, 1.1, 1.2, and 1.3, and the fragment 1.3 region was divided again into fragments 1.3.1, 1.3.2, 1.3.3, and 1.3.4. The final peptide containing specific CHEK2 phosphorylation sites was designated B2P: it has 50 amino acids with four putative substrate sites (shown in red), identified by mass-spectrometric analysis. The mass-spectrometric analysis was performed by using fragments of BRCA2 expressed from bacteria as GST-fusion proteins with either bacterially expressed GST-CHEK2 or immunoprecipitated Flag-CHEK2 from IR-treated tissue culture cells. The right panel shows the in vitro CHEK2 phosphorylation assay for each step of analysis with BRCA2 fragments. GST-BRCA1 fragment containing S988 and GST alone were used as positive and negative controls.
target (Figure 1 , data not shown). Through a series of further subcloning experiments, the putative CHEK2 target sequence was narrowed to 50 amino-acid residues (aa 400 -450), referred to as B2P. (Figures 1 and 2A Serine is well conserved in most mammals (Supplementary data).
To test the contribution of each Serine and Threonine residues to CHEK2-mediated phosphorylation, we undertook site-directed mutagenesis of B2P, substituting unphosphorylatable residues (Serine to Alanine, and Threonine into Valine), either alone or in combination (mutant peptides M1-9, Figure 2B ). Fragments containing single, double, triple, or quadruple mutations were used as substrates for in vitro GST-CHEK2-mediated phosphorylation.
Of peptides with a single substitution, only M4 (targeting 442 Ser) showed a reduction in CHEK2-dependent phosphorylation using either GST-CHEK2 or immunoprecipitated CHEK2 from irradiated cells ( Figure 2B and C). Peptides with multiple substitutions including S442A (M6, M7, M8, M9) also showed reduced CHEK2 phosphorylation, whereas a multisubstituted peptide with an unaltered 442 Ser (M5) had preserved CHEK2 phosphorylation ( Figure 2B ). Taken together, these studies point to 442 Ser as the potentially major CHEK2 substrate in BRCA2, with additional minor targets including 417 Serine, 418 Serine, and 441
Threonine. Robust and specific assays of BRCA2 function are limited, but brca2-deficient cells are known to have a striking increase in chromosomal defects (Patel et al, 1998; Venkitaraman, 2002) . To define a potential functional assay for BRCA2 phosphorylation at residues localised to the B2P fragment, we generated cell lines with tetracycline-regulated inducible expression of this peptide or a mutant peptide with all four substituted CHEK2-target residues. The osteosarcoma cell line U2OS was selected for these experiments, given its near diploid and stable karyotype, wild-type endogenous p53, and the availability of tightly regulated tetracycline-regulatable founder cell lines. Cell lines were generated, with inducible expression of wild-type or mutated (M9) B2P peptide, linked to a nuclear localisation signal (NLS) and a Flag epitope. In multiple cell lines, tightly regulated expression was achievable with both constructs, although the mutant was consistently induced to higher levels than the wild-type peptide ( Figure 3A ). As control, we also generated cells with inducible expression of BRC4 ( Figure 3A) , a BRCT-containing fragment of BRCA2, which has been reported to disrupt the RAD51-dependent function of BRCA2 (Chen et al, 1999) . Inducible expression of wild-type B2P, but not the M9 mutant, led to a reduction in cell proliferation, similar to that observed following induction of BRC4 ( Figure 3B ). As the inactivation of BRCA2 is known to result in spontaneous disruption of chromosome structure (Chen et al, 1999) , we examined chromosome spreads of U2OS cells with inducible expression of B2P using GTG banding. A reproducible increase in chromosome fragments per metaphase was observed 48 h following induction of wild-type B2P, but not the M9 mutant ( Figure 3C and D) . The effect of B2P peptide expression was comparable to that of BRC4 ( Figure 3C and D) . There was no statistically significant difference in mean fragment/metaphase between B2P-WT and BRC4. The mean fragment/metaphase levels between B2P-M9 and BRC4 were significantly different (Po0.0001). Thus, ectopic overexpression of the BRCA2 fragment containing intact CHEK2 phosphorylation sites may disrupt endogenous gene product function, leading to chromosomal instability.
CONCLUDING REMARKS
Our studies suggest a potential functional link between the CHEK2 kinase and the BRCA2 tumour suppressor, which may explain in part the increased incidence of male breast cancer observed in families with germline mutations in both of these genes (Couch et al, 1996; Haraldsson et al, 1998; Meijers-Heijboer et al, 2002) . While factors affecting BRCA2 protein function are poorly understood, two other kinases have recently been implicated in its regulation (Lin et al, 2003; Lee et al, 2004; Esashi et al, 2005) . CDK-dependent phosphorylation of the C-terminal BRCT domain (Ser 3291) has been shown to modulate the BRCA2 -RAD51 interaction in a cell cycle-dependent manner. This interaction was disrupted by ectopic expression of BRCA2-derived peptides containing the phosphorylation target site (Esashi et al, 2005) . In addition, polo-like kinase 1 (PLK1) has been shown to phosphorylate the N terminus of BRCA2, modulating its dissociation from a transcriptional co-activator protein, P/CAF, -S417A  M2 -S418A  M3 -T441V  M4 -S442A   M5 -S417A, T441V  M6 -S417A, S442A  M7 -S418A, S442A  M8 -S417A, S418A, S442A  M9 -S417A, S418A, with intrinsic histone acetyltransferase activity (Lin et al, 2003; Lee et al, 2004) . The effect of CHEK2 on BRCA2 remains to be confirmed in vivo, as does its effect on potential functional properties of BRCA2. Nonetheless, the potential modulation by CHEK2 of both BRCA1 and BRCA2 would point to an important function for this checkpoint kinase in the DNA damage repair pathways implicated in the development of breast cancer. 
